Compare · BSX vs NYXH
BSX vs NYXH
Side-by-side comparison of Boston Scientific Corporation (BSX) and Nyxoah SA (NYXH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and NYXH operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $64.20B, about 954.7x NYXH ($67.2M).
- Over the past year, BSX is down 58.4% and NYXH is down 80.4% - BSX leads by 22.0 points.
- NYXH has been more active in the news (5 items in the past 4 weeks vs 1 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 9 for NYXH).
- Company
- Boston Scientific Corporation
- Nyxoah SA
- Price
- $42.97-0.49%
- $1.52-1.30%
- Market cap
- $64.20B
- $67.2M
- 1M return
- -3.02%
- -1.94%
- 1Y return
- -58.38%
- -80.36%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 1
- 5
- Recent ratings
- 25
- 9
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Nyxoah SA
Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.
Latest BSX
- EVP and CFO Monson Jonathan covered exercise/tax liability with 1,010 shares and converted options into 2,087 shares, increasing direct ownership by 3% to 39,063 units (SEC Form 4)
- SEC Form 11-K filed by Boston Scientific Corporation
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Latest NYXH
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah Announces Preliminary Results for the Second Quarter of 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Nyxoah SA
- Information on the total number of voting rights and shares
- Publication relating to transparency notifications
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah to Host Investor Day in New York on July 8, 2026
- SEC Form SCHEDULE 13G filed by Nyxoah SA
- Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 9, 2026
- Publication relating to transparency notifications